Disfiguring cutaneous, manifestation of sarcoidosis treated with thalidomide: A case report

Journal of the American Academy of Dermatology

Volumn 39, Issue 5 II SUPPL., 1998, Pages 835-838

  Lee, J B ^a   Koblenzer, P S ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOCORTICOID; PREDNISONE; THALIDOMIDE;

ADULT; ARTICLE; CASE REPORT; DOSE RESPONSE; DRUG EFFICACY; FEMALE; HUMAN; HUMAN TISSUE; ORAL DRUG ADMINISTRATION; PARESTHESIA; PRIORITY JOURNAL; SARCOIDOSIS; SKIN BIOPSY; SKIN GRANULOMA; SKIN MANIFESTATION; TREATMENT OUTCOME;

EID: 0031774780     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0190-9622(98)70360-3     Document Type: Article

References (18)

1. JM Gardner-Medwin RJ. Powell Guideline for the clinical use and dispensing of thalidomide Postgrad Med J 70 1994 901 904
2. J. Sheskin Thalidomide in the treatment of lepra reaction Clin Pharmacol Therap 6 1965 303 306
3. S Tseng G Pak K Washenik MK Pomeranz JL. Shupack Rediscovering thalidomide: a review of its mechanism of action, side effects, and potential uses J Am Acad Dermatol 35 1996 969 979
4. LS Newman CS Rose LA. Maier Sarcoidosis N Engl J Med 336 1997 1224 1234
5. C Agostini G Semenzato DG. James Immunological, clinical and molecular aspects of sarcoidosis Mol Aspects Med 18 1997 91 165
6. EP Sampaio EN Sarno R Galilly SA Cohn G Kaplan Thalidomide selectively inhibits tumor necrosis factor-α production by stimulated human monocytes J Exp Med 173 1991 699 703
7. SM McHugh IR Rifkin J Deighton AB Wilson PJ Lachmann CM Lockwood The immunosuppressive drug thalidomide induces T-cell helper cell type 2(Th2) and concomitantly inhibits Th1 cytokine production in mitogen and antigen-stimulated human peripheral blood mononuclear cell cultures Clin Exp Immunol 99 1995 160 167
8. DR Moller M Wysocka BM Greenlee X Ma L Wahl DA Flockhard Inhibition of IL-12 production by thalidomide J Immunol 159 1997 5157 5161
9. DR Moller JD Forman MC Liu PW Noble BM Greenlee P Vyas Enhanced expression of IL-12 associated with Th1 cytokine profiles in active pulmonary sarcoidosis J Immunol 156 1996 4952 4960
10. EJ Shannon F Sandoval JL Krahenbuhl Hydrolysis of thalidomide abrogates its ability to enhance mononuclear cell synthesis of IL-2 as well as its ability to suppress the synthesis of TNF-α Immunopharmacology 36 1997 9 15
11. LP Fernandez PG Schlegel J Baker Y Chen NJ. Chao Does thalidomide affect IL-2 response and production? Exp Hematol 23 1995 978 985
12. M Carlesimo S Giustini A Rossi P Bonaccorsi S. Calvieri Treatment of cutaneous and pulmonary sarcoidosis with thalidomide J Am Acad Dermatol 32 1995 866 869
13. JL Tavares A Wangoo P Dilworth B Marshall S Kotecha RJ. Shaw Thalidomide reduces tumor necrosis factor-alpha production by human alveolar macrophages Respir Med 91 1997 31 39
14. S Ochonisky J Verroust S Bastuji-Garin R Gherardi J. Revuz Thalidomide neuropathy incidence and clinico-electrophysiologic findings in 42 patients Arch Dermatol 130 1994 66 69
15. F Gerr D Hershman R. Letz Vibrotactile threshold measurement for detecting neurotoxicity: reliability and determination of age-and-height-standardized normative values Arch Environ Health 45 1990 148 154
16. JC Arrezo HH Schaumburg CA. Peterson Rapid screening for peripheral neuropathy: a field study with Optacon Neurology 33 1983 626 629
17. V Chaudhry EK Rowinski SE Sartorius RC Donehower DR. Cornblath Peripheral neuropathy from taxol and cisplatin combination chemotherapy: clinical and electrophysiological studies Ann Neurol 35 1994 304 311
18. PA Forsyth C Balmaceda K Peterson AD Seidman P Brasher LM. DeAngelis Prospective study of paclitaxel-induced peripheral neuropathy with quantitative sensory testing J Neurooncol 35 1997 47 53